Targeted drugs for esophageal cancer include trastuzumab, erlotinib, bevacizumab and so on. Trastuzumab is mainly used for the first-line treatment of advanced esophageal adenocarcinoma patients with high expression of HER-2 gene mutation, and generally needs to be combined with chemotherapy in clinical use. Anrotinib and bevacizumab are both targeted drugs that inhibit tumor neoangiogenesis in esophageal cancer. These two targeted drugs do not require genetic testing before administration, and are generally used in the backline treatment of advanced esophageal cancer. Generally, after the first-line and second-line chemotherapy and targeted therapy, if the condition of esophageal cancer progresses again, one can consider choosing the treatment plan of Anrotinib monotherapy or Bevacizumab combined with chemotherapy. All these targeted drugs above have side effects, and the common side effects include rash, cardiotoxicity, high blood pressure, proteinuria, etc. It is necessary to be guided by professional doctors to use the drugs.